JWH-193

JWH-193
Legal status
Legal status	CA: Schedule II; DE: NpSG (Industrial and scientific use only); UK: Class B; US: Schedule I;
Identifiers
	IUPAC name (1-(2-Morpholin-4-ylethyl)indol-3-yl)-4-methylnaphthalen-1-ylmethanone;
JSmol)	Interactive image;
	SMILES c3cccc1c3c(ccc1C)C(=O)c5c2ccccc2n(c5)CCN4CCOCC4;
	InChI InChI=1S/C26H26N2O2/c1-19-10-11-23(21-7-3-2-6-20(19)21)26(29)24-18-28(25-9-5-4-8-22(24)25)13-12-27-14-16-30-17-15-27/h2-11,18H,12-17H2,1H3; Key:ICKWPPYMDARCKJ-UHFFFAOYSA-N;
	(verify)

JWH-193 is a drug from the

naphthoylindole families which acts as a cannabinoid receptor agonist. It was invented by the pharmaceutical company Sanofi-Winthrop in the early 1990s. JWH-193 has a binding affinity at the CB₁ receptor of 6 nM, binding around seven times more tightly than the parent compound JWH-200,^[1]

though with closer to twice the potency of JWH-200 in activity tests.

In the United States, all CB₁ receptor agonists of the 3-(1-naphthoyl)indole class such as JWH-193 are

Schedule I Controlled Substances.^[2]